News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 37–72
- Matches
- 1120
- Sources here
- 19
- Companies here
- 26
Search results
Stored financial headlines
Active search
1120 matching headlines
Ticker or company: OTECMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
BofA Securities Adjusts Sana Biotechnology Price Target to $6 From $7
BofA Securities has lowered its price target for Sana Biotechnology (SANA) to $6 from $7, as reported on August 14, 2026. This adjustment follows other recent news for the company, including its Q2 adjusted loss narrowing and its removal from several Russell Value Benchmarks …
SANA
main company
Sharemaestro market context
Price above Trend Line
52 weeks -0.8%
Trinity Biotech secures $7m from Perceptive Advisors By Investing.com
Trinity Biotech (NASDAQ:TRIB) has secured an additional $7.0 million investment from Perceptive Advisors, its largest financial investor, comprising $2.5 million in new debt and $4.5 million in capitalized interest. This funding will support the company's CGM+ continuous glucose monitoring platform, Trinovium subsidiary, and diagnostics …
TRIB
main company
Sharemaestro market context
Price below Trend Line
52 weeks -75.2% · Next-week setup negative 37.4%
Trinity Biotech Secures Additional $7.0 Million Investment from Perceptive Advisors and Regains Compliance with Nasdaq Minimum Bid Price Requirement
Trinity Biotech (NASDAQ: TRIB) has secured an additional $7.0 million investment from Perceptive Advisors, its largest financial investor, and has regained compliance with Nasdaq's minimum bid price requirement. The investment, consisting of new debt funding and capitalized interest, aims to bolster liquidity for strategic …
TRIB
main company
Sharemaestro market context
Price below Trend Line
52 weeks -75.2% · Next-week setup negative 37.4%
PDS Biotechnology shareholders approve charter amendment and director elections
PDS Biotechnology Corporation shareholders have approved an amendment to the company's certificate of incorporation, increasing the number of authorized common shares from 150 million to 300 million. They also elected two Class B directors, Kamil Ali-Jackson and Ilian Iliev, and ratified KPMG US LLP …
PDSB
main company
Sharemaestro market context
Price below Trend Line
52 weeks -80.6% · Next-week setup negative 41.3%
Moleculin Biotech GAAP EPS of -$1.40 misses by $0.53
* Moleculin Biotech press release [https://seekingalpha.com/pr/20619725-moleculin-biotech-reports-second-quarter-2026-financial-results-and-highlights-continued] (MBRX [https://seekingalpha.com/symbol/MBRX]): Q2 GAAP EPS of -$1.40 misses by $0.53. * As of June 30, 2026, the company had cash and cash equivalents of approximately $7.3 million. Management believes that its cash on hand and cash equivalents as …
MBRX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -95.7% · Next-week setup negative 44.5%
Evercore ISI initiates Alvotech stock with outperform rating
Evercore ISI has initiated coverage on Alvotech SA (NASDAQ:ALVO) with an outperform rating, citing high leverage and past FDA inspection issues but also significant potential for deleveraging with successful biosimilar launches. Despite a substantial debt burden, InvestingPro analysis indicates the stock is currently undervalued. …
ALVO
main company
Sharemaestro market context
Price above Trend Line
52 weeks -52.0% · Next-week setup negative 43.6%
Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial
Moleculin Biotech reported its second-quarter 2026 financial results, highlighting significant progress in its pivotal Phase 2/3 MIRACLE trial for Annamycin in relapsed or refractory AML. Positive interim data showed complete remission rates three times higher than the control group, with enrollment on track for …
MBRX
main company
Sharemaestro market context
Price below Trend Line
52 weeks -95.7% · Next-week setup negative 44.5%
PDS Biotechnology (PDSB) wins approval to double authorized stock and elect directors
PDS Biotechnology Corporation announced that its stockholders approved an amendment to increase the authorized common stock from 150,000,000 to 300,000,000 shares. Additionally, stockholders elected Kamil Ali-Jackson, J.D. and Ilian Iliev, Ph.D. as Class B directors to serve until the 2029 annual meeting. The meeting …
PDSB
main company
Sharemaestro market context
Price below Trend Line
52 weeks -80.6% · Next-week setup negative 41.3%
Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026
Evaxion COPENHAGEN, Denmark, August 14, 2026 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its second quarter 2026 financial results on Thursday August 20, 2026, before opening …
EVAX
main company
Sharemaestro market context
Price below Trend Line
52 weeks +2.8% · Next-week setup negative 42.1%
Dimensional Fund Advisors LP Cuts Stock Holdings in Adaptive Biotechnologies Corporation $ADPT
Dimensional Fund Advisors LP significantly reduced its stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 86.4% in the first quarter, selling over 1.19 million shares and retaining 188,338 shares. Despite this, institutional investors still hold 99.17% of the stock. Adaptive Biotechnologies reported a 21.5% increase …
ADPT
main company
Sharemaestro market context
Trend signal active
52 weeks +90.3% · Next-week setup positive 58.0%
RBC Initiates Krystal Biotech at Outperform, With $400 Price Target
RBC Capital Markets has initiated coverage on Krystal Biotech with an Outperform rating and a $400 price target, citing strong positioning for future gains from its product VYJUVEK and a promising pipeline. The biotech company, which specializes in genetic medicines, recently reported Q2 2026 …
KRYS
main company
Sharemaestro market context
Trend signal active
52 weeks +120.8%
XBiotech (NASDAQ:XBIT) Issues Quarterly Earnings Results, Misses Estimates By $0.25 EPS
XBiotech (NASDAQ:XBIT) reported a quarterly loss of $0.22 per share, significantly missing analysts' consensus estimate of a $0.03 profit by $0.25. Following the announcement, XBIT shares fell by $0.13 to $2.33, nearing its 52-week low, and the company's market capitalization is approximately $71 million. …
XBIT
main company
Sharemaestro market context
Price below Trend Line
52 weeks -28.1% · Next-week setup negative 42.3%
Form 8K EDESA BIOTECH For: 13 August By Investing.com
This article reports that EDESA BIOTECH filed a Form 8K on August 13th, as tracked by Investing.com. The filing details are not provided within the article itself, but it highlights the company EDSA with a stock performance of +2.45%. The piece is primarily a …
EDSA
main company
Sharemaestro market context
Price below Trend Line
52 weeks +122.9%
Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript
Image source: The Motley Fool. DATE Wednesday, Aug. 12, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Co-Founder, President and Chief Executive Officer - Claude MaraouiChief Financial Officer - Joseph BeneschChief Operating Officer and General Counsel - Ramsey AlloushSenior Director of Corporate Operations - Jaclyn …
Sharemaestro market context Price above Trend Line 52 weeks +29.1% · Next-week setup negative 44.6%